GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
N

Nfl Biosciences SAS ALNFL.PA · EUR

Health Care · Euronext Paris · 🇫🇷 France

Compare

0.39

+11.92%

Close of 9 Nov 2026, in EUR

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Nfl Biosciences SAS

Its shares trade on Euronext Paris under the ticker ALNFL.PA. It has been listed since 5 July 2021. In the fiscal year to 31 December 2024, it reported revenue of €46 and a net loss of €2.1m. At that date it held total assets of €3.6m and shareholders' equity of €976,430.

NFL Biosciences SAS is a biotechnology company, which engages in the development of botanical drug candidates for the treatment of tobacco addiction and neurological diseases. The company is headquartered in Castelnau-Le-Lez, Occitanie. The company went IPO on 2021-07-05. The firm's products help cure addictions through an approach based on botanical pharmaceutical agents. The company develops NFL-101, a patented, botanical drug candidate that aims at increasing the odds of quitting for smokers willing to quit. The firm applies scientific approach to other drug candidate with an initial focus targeting the growing addiction to cannabis.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Health Care
Industry
Biotechnology
Listed since
5 Jul 2021
Employees
3

Leadership

Pay as last reported

  • Mr. Bruno LafontChairman of the Board, Managing Director
  • Mr. Ignacio FausDeputy Managing Director, Director
  • Mr. Francis AhnerDirector
  • Mrs. Dominique CoteDirector
  • Mr. Yannick PletanDirector

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • NFL Biosciences SAS develops NFL-101, a patented botanical drug candidate for smoking cessation.
  • The company focuses on botanical pharmaceutical agents targeting tobacco addiction and cannabis addiction.
  • NFL Biosciences SAS has a small team of 3 full-time employees with a clear focus on drug development.

Weaknesses

  • The company has only 3 full-time employees, limiting its operational capacity.
  • NFL Biosciences SAS is a newly listed company with limited market presence since 2021.
  • The firm's product portfolio is currently limited to NFL-101 and early-stage cannabis addiction candidates.

Opportunities

  • Growing market for botanical drug candidates targeting tobacco addiction in France.
  • Expanding opportunities in the cannabis addiction treatment sector within the Health Care industry.
  • Potential for FDA approval of NFL-101 in the United States market.

Threats

  • Competition from established pharmaceutical companies in the Health Care sector.
  • Regulatory challenges in the approval process for botanical drug candidates.
  • Market volatility affecting small biotechnology firms like NFL Biosciences SAS.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.